Literature DB >> 18332230

Multiple myeloma.

Robert A Kyle1, S Vincent Rajkumar.   

Abstract

Multiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. In this paper, we present a historically focused review of the disease, from the description of the first case in 1844 to the present. The evolution of drug therapy and stem-cell transplantation for the treatment of myeloma, as well as the development of new agents, is discussed. We also provide an update on current concepts of diagnosis and therapy, with an emphasis on how treatments have emerged from a historical perspective after certain important discoveries and the results of experimental studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332230      PMCID: PMC2265446          DOI: 10.1182/blood-2007-10-078022

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  81 in total

1.  [Clinical experiences with sarcolysin in neoplastic diseases].

Authors:  N BLOKHIN; L LARIONOV; N PEREVODCHIKOVA; L CHEBOTAREVA; N MERKULOVA
Journal:  Ann N Y Acad Sci       Date:  1958-04-24       Impact factor: 5.691

2.  Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Authors:  Robert Z Orlowski; Arnon Nagler; Pieter Sonneveld; Joan Bladé; Roman Hajek; Andrew Spencer; Jesús San Miguel; Tadeusz Robak; Anna Dmoszynska; Noemi Horvath; Ivan Spicka; Heather J Sutherland; Alexander N Suvorov; Sen H Zhuang; Trilok Parekh; Liang Xiu; Zhilong Yuan; Wayne Rackoff; Jean-Luc Harousseau
Journal:  J Clin Oncol       Date:  2007-08-06       Impact factor: 44.544

3.  Urethane and stilbamidine in multiple myeloma report on two cases.

Authors:  N ALWALL
Journal:  Lancet       Date:  1947-09-13       Impact factor: 79.321

4.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

Authors:  S Vincent Rajkumar; Emily Blood; David Vesole; Rafael Fonseca; Philip R Greipp
Journal:  J Clin Oncol       Date:  2005-12-19       Impact factor: 44.544

5.  Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.

Authors:  Sundar Jagannath; Brian G M Durie; Jeffrey Wolf; Elber Camacho; David Irwin; Jose Lutzky; Marti McKinley; Eli Gabayan; Amitabha Mazumder; David Schenkein; John Crowley
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

6.  Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme.

Authors:  S Wilk; M Orlowski
Journal:  J Neurochem       Date:  1980-11       Impact factor: 5.372

7.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

8.  A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.

Authors:  A K Stewart; P L Bergsagel; P R Greipp; A Dispenzieri; M A Gertz; S R Hayman; S Kumar; M Q Lacy; J A Lust; S J Russell; T E Witzig; S R Zeldenrust; D Dingli; C B Reeder; V Roy; R A Kyle; S V Rajkumar; R Fonseca
Journal:  Leukemia       Date:  2007-01-18       Impact factor: 11.528

9.  Multiple myeloma treated with high dose intravenous melphalan.

Authors:  P J Selby; T J McElwain; A C Nandi; T J Perren; R L Powles; C R Tillyer; R J Osborne; M L Slevin; J S Malpas
Journal:  Br J Haematol       Date:  1987-05       Impact factor: 6.998

10.  High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.

Authors:  T J McElwain; R L Powles
Journal:  Lancet       Date:  1983-10-08       Impact factor: 79.321

View more
  324 in total

1.  Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka.

Authors:  Tsutomu Kobayashi; Junya Kuroda; Kazuho Shimura; Teruaki Akaogi; Eri Kawata; Miki Kiyota; Takashi Tanaka; Yuri Kamitsuji; Satoshi Murakami; Mayumi Hatsuse; Akira Okano; Toshiki Iwai; Satomi Ueda; Masahiko Koshida; Hitoji Uchiyama; Yosuke Matsumoto; Hiroto Kaneko; Nobuhiko Uoshima; Yutaka Ueda; Yutaka Kobayashi; Chihiro Shimazaki; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2010-10-07       Impact factor: 2.490

2.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

3.  Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.

Authors:  Miki Kiyota; Tsutomu Kobayashi; Shinichi Fuchida; Mio Yamamoto-Sugitani; Muneo Ohshiro; Yuji Shimura; Shinsuke Mizutani; Hisao Nagoshi; Nana Sasaki; Ryuko Nakayama; Yoshiaki Chinen; Natsumi Sakamoto; Hitoji Uchiyama; Yosuke Matsumoto; Shigeo Horiike; Chihiro Shimazaki; Junya Kuroda; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2012-03-17       Impact factor: 2.490

4.  Successful bortezomib treatment in combination with dexamethasone and thalidomide for previously untreated epidural plasmacytoma.

Authors:  Zhiyong Zeng; Ling Zheng; Junfang Lin; Junmin Chen
Journal:  Oncol Lett       Date:  2011-12-28       Impact factor: 2.967

5.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

6.  Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.

Authors:  S Hong; H Li; J Qian; J Yang; Y Lu; Q Yi
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

7.  Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma.

Authors:  Stavroula Baritaki; Sara Huerta-Yepez; Ma da Lourdas Cabrava-Haimandez; Marialuisa Sensi; Silvana Canevari; Massimo Libra; Manuel Penichet; Haiming Chen; James R Berenson; Benjamin Bonavida
Journal:  For Immunopathol Dis Therap       Date:  2011-04-01

8.  Multiple myeloma: an update.

Authors:  Khalil Al-Farsi
Journal:  Oman Med J       Date:  2013-01

9.  Anthelmintic pyrvinium pamoate blocks Wnt/β-catenin and induces apoptosis in multiple myeloma cells.

Authors:  Fang Xu; Yingjie Zhu; Yuhong Lu; Zhi Yu; Jun Zhong; Yangqiu Li; Jingxuan Pan
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

10.  IgM multiple myeloma with an extremely rare non-aggressive presentation: A case report.

Authors:  Thomas Greuter; Martin Browne; Corina Dommann-Scherrer; Daniel Binder; Christoph Renner; Ursula Kapp
Journal:  Oncol Lett       Date:  2016-08-17       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.